81937-41-9

Basic information

• Product Name: N-Acetoacetanthranilic acid methyl ester
• Synonyms: N-Acetoacetanthranilic acid methyl ester
• CAS NO: 81937-41-9
• Molecular Formula: C₁₂H₁₃NO₄
• Molecular Weight: 235.23592
• Mol File: 81937-41-9.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-Acetoacetanthranilic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: N-Acetoacetanthranilic acid methyl ester(81937-41-9)
• EPA Substance Registry System: N-Acetoacetanthranilic acid methyl ester(81937-41-9)

Safety Data

• Hazardous Substances Data: 81937-41-9(Hazardous Substances Data)

Upstream product

• 674-82-8 4-methyleneoxetan-2-one 
• 134-20-3 2-carbomethoxyaniline 
• 141-97-9 ethyl acetoacetate 
• 5394-63-8 2,2,6-trimethyl-4H-1,3-dioxin-4-one 

Downstream Products

• 26138-64-7 3-acetyl-2,4-dihydroxyquinoline 
• 26138-64-7 4-hydroxy-3-acetyl-1H-quinoline-2-one 
• 69065-89-0 methyl N-(2-methoxycarbonylphenyl)oxalamate 
• 671758-27-3 C₁₈H₁₃NO₃ 
• 163232-52-8 4-hydroxy-3-[3-(4-methoxyphenyl)-1-oxo-2-propen-1-yl]-2(1Η)-quinolinone 
• 163232-53-9 C₁₈H₁₂ClNO₃ 
• 1333500-25-6 C₁₈H₁₂FNO₃ 
• 1333500-26-7 4-hydroxy-3-[3-(4-nitrophenyl)-1-oxo-2-propen-1-yl]-2(1Η)-quinolinone 
• 1333500-27-8 C₁₈H₁₃NO₄ 
• 1333500-28-9 C₁₈H₁₃NO₄ 
• 163232-50-6 C₂₀H₁₈N₂O₃ 
• 1333500-29-0 C₁₉H₁₅NO₅ 

Relevant articles and documents

Structure-Based Optimization of Small Molecule Human Galactokinase Inhibitors

Classic galactosemia is a rare disease caused by inherited deficiency of galactose-1 phosphate uridylyltransferase (GALT). Accumulation of galactose-1 phosphate (gal-1P) is thought to be the major cause of the chronic complications associated with this disease, which currently has no treatment. Inhibiting galactokinase (GALK1), the enzyme that generates galactose-1 phosphate, has been proposed as a novel strategy for treating classic galactosemia. Our previous work identified a highly selective unique dihydropyrimidine inhibitor against GALK1. With the determination of a co-crystal structure of this inhibitor with human GALK1, we initiated a structure-based structure-activity relationship (SAR) optimization campaign that yielded novel analogs with potent biochemical inhibition (IC50 100 nM). Lead compounds were also able to prevent gal-1P accumulation in patient-derived cells at low micromolar concentrations and have pharmacokinetic properties suitable for evaluation in rodent models of galactosemia.

L-Proline as an efficient catalyst for synthesis of N-heterocyclic chalcones as potential antibacterial agents

The condensation of 4-hydroxy-3-acetyl-1H-quinoline-2-one 1 and substitutedbenzaldehydes 2a-i in DMSO solution at room temperature yields quinolone chalcone derivatives 3a-i. L-Proline has been found to be an efficient catalyst for this condensation between 1 and 2. Only 5 mol% of the catalyst is necessary to achieve good yields of the products. Reactions proceed smoothly with variations of the substituents. 1 itself is synthesized by the acylation of commercially available methyl anthranilate 4 with acetoacetic ester 5 in refluxing xylene and subsequent Dieckman intramolcular cyclization of the intermediary 2-methoxycarbonylanilide 6.

4-Hydroxy-2-quinolones. 152*. 3-acetyl-4-hydroxy-2-oxo-1,2- dihydroquinoline and its biologically active derivatives

A synthesis and study of the spatial structure of 3-acetyl-4-hydroxy-2-oxo- 1,2-dihydroquinoline have been carried. 1-R-4-hydroxy-2-oxo-1,2- dihydroquinoline-3-carboxylic acids [1-(4-hydroxy-2-oxo-1,2-dihydroquinolin-3- yl)ethylidene]hydrazides were prepared from this compound by two routes. A comparative analysis of the antitubercular properties of the synthesized compounds and of the closely structurally related N,N′-di(1-R-4-hydroxy-2- oxo-1,2-dihydroquinoline-3-carbonyl)hydrazines has been performed.